Serum miR-21 and miR-155 expression in idiopathic pulmonary fibrosis

Li, Ping; Zhao, Guoqiang; Chen, Tengfei; Chang, Jingxia; Wang, Huaqi; Chen, Shanshan; Zhang, Guojun

doi:10.3109/02770903.2013.822080

Cited by 52 publications

(38 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Levels of miR-21 and miR-155 were significantly elevated in IPF patient serum (Li et al, 2013(Li et al, , 2014, consistent with findings from the cell-based mouse and human studies discussed earlier (Pottier et al, 2009;Liu et al, 2010;Yamada et al, 2013). The upregulation of serum miR-21 was confirmed as a predictor of poor prognosis by two other groups Makiguchi et al, 2016).…”

Section: Clinical Use Of Mirnas In Respiratory Disease Mirnas As Biomsupporting

confidence: 87%

The role of microRNAs in chronic respiratory disease: recent insights

Stolzenburg¹,

Harris²

2017

Biological Chemistry

View full text Add to dashboard Cite

Chronic respiratory diseases encompass a group of diverse conditions affecting the airways, which all impair lung function over time. They include cystic fibrosis (CF), idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and asthma, which together affect hundreds of millions of people worldwide. MicroRNAs (miRNAs), a class of small non-coding RNAs involved in post-transcriptional gene repression, are now recognized as major regulators in the development and progression of chronic lung disease. Alterations in miRNA abundance occur in lung tissue, inflammatory cells, and freely circulating in blood and are thought to function both as drivers and modifiers of disease. Their importance in lung pathology has prompted the development of miRNA-based therapies and biomarker tools. Here, we review the current literature on miRNA expression and function in chronic respiratory disease and highlight further research that is needed to propel miRNA treatments for lung disorders towards the clinic.

show abstract

Section: Clinical Use Of Mirnas In Respiratory Disease Mirnas As Biomsupporting

confidence: 87%

The role of microRNAs in chronic respiratory disease: recent insights

Stolzenburg¹,

Harris²

2017

Biological Chemistry

View full text Add to dashboard Cite

show abstract

“…Taken together, these data suggest that miR-21 functions in a positive feed-back loop to promote pulmonary fibrosis [52]. The upregulation of miR-21 was validated independently in several lung fibrosis models as well as in human subjects, such as in the serum of patient with IPF [75,54]. All these findings suggest the critical role of miR-21 in the pathogenesis of pulmonary fibrosis and also indicate miR-21 as a putative therapeutic target for developing miRNA based strategies for IPF treatment.…”

Section: Mirnas and Lung Fibrosismentioning

confidence: 97%

The code of non-coding RNAs in lung fibrosis

Xie

Thannickal

Liu

2015

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

The pathogenesis of pulmonary fibrosis is a complicated and complex process that involves phenotypic abnormalities of a variety of cell types and dysregulations of multiple signaling pathways. There are numerous genetic, epigenetic and posttranscriptional mechanisms that have been identified to participate in the pathogenesis of this disease. However, efficacious therapeutics developed from these studies have been disappointingly limited. In the past several years, a group of new molecules, i.e. non-coding RNAs (ncRNAs), has been increasingly appreciated to have critical roles in the pathological progression of lung fibrosis. In this review, we summarize the recent findings on the roles of ncRNAs in the pathogenesis of this disorder. We analyze the translational potential of this group of molecules in treating lung fibrosis. We also discuss challenges and future opportunities of studying and utilizing ncRNAs in lung fibrosis.

show abstract

“…The detection of specific miRNA alterations in serum samples of IPF patients suggests that miRNA could be used as a noninvasive screening tool for IPF in routine clinical practice, establishing more reliable biomarkers [126,128]. Novel treatment strategies based on epigenetic drugs, such as 5-aza-2′-deoxycytidine and decitabine [129], or exogenous administration of miRNAs, could also prove beneficial for management of IPF patients.…”

Section: Biomarkers In Ipf and Osamentioning

confidence: 99%

“…The first report revealing the potential role of miRNAs in IPF demonstrated impressively by array analysis that 10% of the miRNAs were significantly different between IPF and control samples [121]. A series of elegant studies followed evaluating the miRNAs expression levels in IPF, such as the downregulation of members of Let-7, miR-29, miR-30, miR-31, miR-200, miR-326 and the miR-17-92 cluster, and the upregulation of miR-155 and miR-21 [121][122][123][124][125][126][127].…”

Section: Biomarkers In Ipf and Osamentioning

confidence: 99%

Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night

et al. 2015

View full text Add to dashboard Cite

The prevalence of obstructive sleep apnoea (OSA) is continuously increasing in patients with idiopathic pulmonary fibrosis (IPF) and, for the first time, the recent IPF guidelines recognise OSA as an important associated comorbidity that can affect patient's survival. Thus, it becomes conceivable that clinicians should refer patients with newly diagnosed IPF to sleep centres for the diagnosis and treatment of OSA as well as for addressing issues regarding the reduced compliance of patients with continuous positive airway pressure therapy. The discovery of biomarkers common to both disorders may help early diagnosis, institution of the most appropriate treatment and follow-up of patients. Better understanding of epigenetic changes may provide useful information about pathogenesis and, possibly, development of new drugs for a dismal disease like IPF. @ERSpublications It is now believed that IPF and sleep disorders can coexist in the same patient

show abstract

Serum miR-21 and miR-155 expression in idiopathic pulmonary fibrosis

Cited by 52 publications

References 31 publications

The role of microRNAs in chronic respiratory disease: recent insights

The role of microRNAs in chronic respiratory disease: recent insights

The code of non-coding RNAs in lung fibrosis

Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night

Contact Info

Product

Resources

About